[424B3] CERO THERAPEUTICS HOLDINGS, INC. Prospectus Filed Pursuant to Rule 424(b)(3)
Cero Therapeutics Holdings, Inc. filed a Prospectus Supplement updating its S-1 covering 12,500,000 shares of common stock, incorporating a Current Report on Form 8-K.
The update discloses that a Nasdaq Hearings Panel denied continued listing of the common stock, with trading on Nasdaq to be suspended at the open on October 31, 2025. The company has requested review by the Nasdaq Listing and Hearing Review Council and has begun the process to trade on the OTC Markets, noting that OTC venues are typically less liquid and may adversely affect trading price and volume. Cero is also considering other exchange listings.
The company states it intends to continue its clinical trials, including ongoing dosing. Early observations for CER-1236 in three AML patients at an initial low dose included rapid cell expansion and no observed toxicity, and one patient continues on trial; the company plans to advance to a higher dose and is evaluating financing alternatives to fund operations.
Cero Therapeutics Holdings, Inc. ha depositato un Prospetto Integrativo aggiornando il suo S-1 che copre 12,500,000 azioni comuni, incorporando un Rapporto Corrente sul modulo 8-K.
L'aggiornamento rende noto che un Nasdaq Hearings Panel ha negato la continuazione della listità delle azioni comuni, con la sospensione della negoziazione su Nasdaq all'apertura del 31 ottobre 2025. L'azienda ha richiesto una revisione al Nasdaq Listing and Hearing Review Council ed ha avviato il processo per negoziare sui mercati OTC, osservando che le sedi OTC sono tipicamente meno liquide e possono influire negativamente sui prezzi e sui volumi di negoziazione. Cero sta valutando anche altre quotazioni su altre borse.
L'azienda dichiara di voler proseguire i propri trial clinici, inclusi i dosaggi in corso. Osservazioni iniziali su CER-1236 in tre pazienti AML a una dose iniziale bassa includonovano rapida espansione cellulare e nessuna tossicità osservata, e un paziente continua nello studio; l'azienda intende passare a una dose superiore e sta valutando alternative di finanziamento per finanziare le operazioni.
Cero Therapeutics Holdings, Inc. presentó un Suplemento de Prospecto actualizando su S-1 que cubre 12,500,000 acciones ordinarias, incorporando un Informe Actual en el Formulario 8-K.
La actualización divulga que un Panel de Audiencias de Nasdaq negó la continuación de la cotización de las acciones ordinarias, con la negociación en Nasdaq suspendida al inicio de la sesión el 31 de octubre de 2025. La empresa ha solicitado una revisión ante el Nasdaq Listing and Hearing Review Council y ha iniciado el proceso para negociar en los Mercados OTC, señalando que las plataformas OTC suelen ser menos líquidas y pueden afectar negativamente el precio y el volumen de negociación. Cero también está considerando otras cotizaciones en bolsas.
La empresa afirma que continuará sus ensayos clínicos, incluida la dosificación en curso. Las observaciones iniciales de CER-1236 en tres pacientes con AML a una dosis inicial baja incluyeron rápida expansión celular y ninguna toxicidad observada, y un paciente continúa en el ensayo; la empresa planea pasar a una dosis más alta y está evaluando alternativas de financiación para financiar sus operaciones.
Cero Therapeutics Holdings, Inc.는 12,500,000주 공통주를 담은 S-1을 업데이트하는 Prospectus 보충서를 제출했다, 현재 Form 8-K의 보고서를 포함한다.
업데이트는 Nasdaq 청문 패널이 보통주 상장 지속을 거부했고 Nasdaq에서의 거래가 2025년 10월 31일 개장 시점에 중단될 것이라고 공시한다. 회사는 Nasdaq Listing and Hearing Review Council에 의한 검토를 요청했고 OTC 시장에서 거래를 시작하는 절차를 시작했으며 OTC 거래소가 일반적으로 유동성이 낮아 거래 가격과 거래량에 부정적 영향을 미칠 수 있다고 언급했다. Cero는 또한 다른 거래소 상장도 고려 중이다.
회사는 임상 시험을 계속할 계획이며, 진행 중인 투여를 포함한다. CER-1236의 AML 세 명의 환자에서 초기 저용량으로 관찰된 결과는 빠른 세포 확장과 독성 관찰 없음이었고 한 환자는 여전히 시험에 참여하고 있다; 회사는 더 높은 용량으로 진행할 계획이며 운영 자금을 조달하기 위한 재정 옵션을 평가 중이다.
Cero Therapeutics Holdings, Inc. a déposé un Prospectus Supplémentaire actualisant son S-1 couvrant 12 500 000 actions ordinaires, intégrant un Rapport Actuel sur le Formulaire 8-K.
La mise à jour divulgue qu'un Nasdaq Hearings Panel a refusé la poursuite de la cotation des actions ordinaires, avec suspension des échanges sur Nasdaq à l'ouverture du 31 octobre 2025. L'entreprise a demandé un réexamen auprès du Nasdaq Listing and Hearing Review Council et a entamé le processus pour négocier sur les marchés OTC, notant que les lieux OTC sont généralement moins liquides et peuvent affecter négativement le prix et le volume des transactions. Cero examine également d'autres cotations sur des bourses.
L'entreprise déclare qu'elle entend poursuivre ses essais cliniques, y compris les dosages en cours. Les observations préliminaires pour CER-1236 chez trois patients atteints de AML à une dose initiale faible ont montré une expansion rapide des cellules et aucune toxicité observée, et un patient continue l'essai; l'entreprise prévoit d'avancer à une dose plus élevée et évalue des alternatives de financement pour financer ses opérations.
Cero Therapeutics Holdings, Inc. hat einen Prospekt-Supplement eingereicht, der seinen S-1 aktualisiert und 12.500.000 Stammaktien abdeckt, der einen aktuellen Bericht auf Formular 8-K einbezieht.
Das Update gibt bekannt, dass ein Nasdaq Hearings Panel die fortgesetzte Listung der Stammaktien abgelehnt hat, mit Handelsaussetzung an der Nasdaq zum Handelsbeginn am 31. Oktober 2025. Das Unternehmen hat eine Überprüfung beim Nasdaq Listing and Hearing Review Council beantragt und hat begonnen, den Prozess für den Handel an den OTC-Märkten zu starten, wobei darauf hingewiesen wird, dass OTC-Handelsplätze in der Regel weniger liquide sind und sich negativ auf den Handelskurs und das Handelsvolumen auswirken können. Cero erwägt auch andere Börsennotierungen.
Das Unternehmen erklärt, dass es seine klinischen Studien fortsetzen will, einschließlich laufender Dosierungen. Erste Beobachtungen zu CER-1236 bei drei AML-Patienten bei einer anfänglichen niedrigen Dosis zeigten eine rasche Zellexpansion und keine beobachtete Toxizität, und ein Patient setzt die Studie fort; das Unternehmen plant, zu einer höheren Dosis überzugehen, und bewertet Finanzierungsmöglichkeiten, um den Betrieb zu finanzieren.
قامت شركة Cero Therapeutics Holdings, Inc. بتقديم ملحق نشرة اكتتاب يقوم بتحديث نموذج S-1 الخاص بها ويغطي 12,500,000 سهم من الأسهم العادية، مضمنًا تقريرًا حاليًا في النموذج 8-K.
يفصح التحديث أن لجنة جلسات الاستماع في ناسداك رفضت استمرار إدراج الأسهم العادية، مع تعليق التداول على ناسداك عند الافتتاح في 31 أكتوبر 2025. طلبت الشركة مراجعة من قبل مجلس مراجعة إدراج وجلسات الاستماع في ناسداك وبدأت عملية التداول في أسواق OTC، مشيرة إلى أن منصّات OTC عادة ما تكون أقل سيولة وقد تؤثر سلبًا على سعر التداول وحجمه. كما تنظر Cero في إدراجات في بورصات أخرى.
وذكرت الشركة أنها ستواصل تجاربها السريرية، بما في ذلك الجرعات المستمرة. الملاحظات المبكرة لـ CER-1236 لدى ثلاثة مرضى AML عند جرعة منخفضة ابتدائية تضمنت توسيعًا سريعًا للخلايا وعدم ملاحظة سمية، ولا يزال أحد المرضى في الدراسة؛ تخطط الشركة للانتقال إلى جرعة أعلى وتقيّم خيارات تمويل لتمويل العمليات.
- None.
- None.
Insights
Nasdaq suspension introduces liquidity risk; OTC shift under review.
Cero Therapeutics reports a Nasdaq Hearings Panel denial, with trading suspension effective at the open on
Administrative supplements like this are typically neutral, but a venue downgrade can widen spreads and reduce institutional participation. Proceeds or capital actions are not described here; the supplement primarily conveys the listing outcome and paths under consideration.
The company indicates ongoing clinical activity and plans to escalate dosing for CER-1236, while reviewing financing alternatives. Actual market impact depends on listing outcomes and any subsequent funding steps disclosed in future filings.
Cero Therapeutics Holdings, Inc. ha depositato un Prospetto Integrativo aggiornando il suo S-1 che copre 12,500,000 azioni comuni, incorporando un Rapporto Corrente sul modulo 8-K.
L'aggiornamento rende noto che un Nasdaq Hearings Panel ha negato la continuazione della listità delle azioni comuni, con la sospensione della negoziazione su Nasdaq all'apertura del 31 ottobre 2025. L'azienda ha richiesto una revisione al Nasdaq Listing and Hearing Review Council ed ha avviato il processo per negoziare sui mercati OTC, osservando che le sedi OTC sono tipicamente meno liquide e possono influire negativamente sui prezzi e sui volumi di negoziazione. Cero sta valutando anche altre quotazioni su altre borse.
L'azienda dichiara di voler proseguire i propri trial clinici, inclusi i dosaggi in corso. Osservazioni iniziali su CER-1236 in tre pazienti AML a una dose iniziale bassa includonovano rapida espansione cellulare e nessuna tossicità osservata, e un paziente continua nello studio; l'azienda intende passare a una dose superiore e sta valutando alternative di finanziamento per finanziare le operazioni.
Cero Therapeutics Holdings, Inc. presentó un Suplemento de Prospecto actualizando su S-1 que cubre 12,500,000 acciones ordinarias, incorporando un Informe Actual en el Formulario 8-K.
La actualización divulga que un Panel de Audiencias de Nasdaq negó la continuación de la cotización de las acciones ordinarias, con la negociación en Nasdaq suspendida al inicio de la sesión el 31 de octubre de 2025. La empresa ha solicitado una revisión ante el Nasdaq Listing and Hearing Review Council y ha iniciado el proceso para negociar en los Mercados OTC, señalando que las plataformas OTC suelen ser menos líquidas y pueden afectar negativamente el precio y el volumen de negociación. Cero también está considerando otras cotizaciones en bolsas.
La empresa afirma que continuará sus ensayos clínicos, incluida la dosificación en curso. Las observaciones iniciales de CER-1236 en tres pacientes con AML a una dosis inicial baja incluyeron rápida expansión celular y ninguna toxicidad observada, y un paciente continúa en el ensayo; la empresa planea pasar a una dosis más alta y está evaluando alternativas de financiación para financiar sus operaciones.
Cero Therapeutics Holdings, Inc.는 12,500,000주 공통주를 담은 S-1을 업데이트하는 Prospectus 보충서를 제출했다, 현재 Form 8-K의 보고서를 포함한다.
업데이트는 Nasdaq 청문 패널이 보통주 상장 지속을 거부했고 Nasdaq에서의 거래가 2025년 10월 31일 개장 시점에 중단될 것이라고 공시한다. 회사는 Nasdaq Listing and Hearing Review Council에 의한 검토를 요청했고 OTC 시장에서 거래를 시작하는 절차를 시작했으며 OTC 거래소가 일반적으로 유동성이 낮아 거래 가격과 거래량에 부정적 영향을 미칠 수 있다고 언급했다. Cero는 또한 다른 거래소 상장도 고려 중이다.
회사는 임상 시험을 계속할 계획이며, 진행 중인 투여를 포함한다. CER-1236의 AML 세 명의 환자에서 초기 저용량으로 관찰된 결과는 빠른 세포 확장과 독성 관찰 없음이었고 한 환자는 여전히 시험에 참여하고 있다; 회사는 더 높은 용량으로 진행할 계획이며 운영 자금을 조달하기 위한 재정 옵션을 평가 중이다.
Cero Therapeutics Holdings, Inc. a déposé un Prospectus Supplémentaire actualisant son S-1 couvrant 12 500 000 actions ordinaires, intégrant un Rapport Actuel sur le Formulaire 8-K.
La mise à jour divulgue qu'un Nasdaq Hearings Panel a refusé la poursuite de la cotation des actions ordinaires, avec suspension des échanges sur Nasdaq à l'ouverture du 31 octobre 2025. L'entreprise a demandé un réexamen auprès du Nasdaq Listing and Hearing Review Council et a entamé le processus pour négocier sur les marchés OTC, notant que les lieux OTC sont généralement moins liquides et peuvent affecter négativement le prix et le volume des transactions. Cero examine également d'autres cotations sur des bourses.
L'entreprise déclare qu'elle entend poursuivre ses essais cliniques, y compris les dosages en cours. Les observations préliminaires pour CER-1236 chez trois patients atteints de AML à une dose initiale faible ont montré une expansion rapide des cellules et aucune toxicité observée, et un patient continue l'essai; l'entreprise prévoit d'avancer à une dose plus élevée et évalue des alternatives de financement pour financer ses opérations.
Cero Therapeutics Holdings, Inc. hat einen Prospekt-Supplement eingereicht, der seinen S-1 aktualisiert und 12.500.000 Stammaktien abdeckt, der einen aktuellen Bericht auf Formular 8-K einbezieht.
Das Update gibt bekannt, dass ein Nasdaq Hearings Panel die fortgesetzte Listung der Stammaktien abgelehnt hat, mit Handelsaussetzung an der Nasdaq zum Handelsbeginn am 31. Oktober 2025. Das Unternehmen hat eine Überprüfung beim Nasdaq Listing and Hearing Review Council beantragt und hat begonnen, den Prozess für den Handel an den OTC-Märkten zu starten, wobei darauf hingewiesen wird, dass OTC-Handelsplätze in der Regel weniger liquide sind und sich negativ auf den Handelskurs und das Handelsvolumen auswirken können. Cero erwägt auch andere Börsennotierungen.
Das Unternehmen erklärt, dass es seine klinischen Studien fortsetzen will, einschließlich laufender Dosierungen. Erste Beobachtungen zu CER-1236 bei drei AML-Patienten bei einer anfänglichen niedrigen Dosis zeigten eine rasche Zellexpansion und keine beobachtete Toxizität, und ein Patient setzt die Studie fort; das Unternehmen plant, zu einer höheren Dosis überzugehen, und bewertet Finanzierungsmöglichkeiten, um den Betrieb zu finanzieren.
قامت شركة Cero Therapeutics Holdings, Inc. بتقديم ملحق نشرة اكتتاب يقوم بتحديث نموذج S-1 الخاص بها ويغطي 12,500,000 سهم من الأسهم العادية، مضمنًا تقريرًا حاليًا في النموذج 8-K.
يفصح التحديث أن لجنة جلسات الاستماع في ناسداك رفضت استمرار إدراج الأسهم العادية، مع تعليق التداول على ناسداك عند الافتتاح في 31 أكتوبر 2025. طلبت الشركة مراجعة من قبل مجلس مراجعة إدراج وجلسات الاستماع في ناسداك وبدأت عملية التداول في أسواق OTC، مشيرة إلى أن منصّات OTC عادة ما تكون أقل سيولة وقد تؤثر سلبًا على سعر التداول وحجمه. كما تنظر Cero في إدراجات في بورصات أخرى.
وذكرت الشركة أنها ستواصل تجاربها السريرية، بما في ذلك الجرعات المستمرة. الملاحظات المبكرة لـ CER-1236 لدى ثلاثة مرضى AML عند جرعة منخفضة ابتدائية تضمنت توسيعًا سريعًا للخلايا وعدم ملاحظة سمية، ولا يزال أحد المرضى في الدراسة؛ تخطط الشركة للانتقال إلى جرعة أعلى وتقيّم خيارات تمويل لتمويل العمليات.
Filed Pursuant to Rule 424(b)(3)
Registration No. 333-288816
Prospectus Supplement No. 5
(To Prospectus dated July 21, 2025, as supplemented by
Prospectus Supplement No. 1, dated August 22, 2025
Prospectus Supplement No. 2, dated September 4, 2025
Prospectus Supplement No. 3, dated September 5, 2025
Prospectus Supplement No. 4, dated October 23, 2025)
CERO THERAPEUTICS HOLDINGS, INC.
12,500,000 Shares of Common Stock
This prospectus supplement no. 5 (this “Prospectus Supplement”) amends and supplements the prospectus dated July 21, 2025 (as may be supplemented or amended from time to time, the “Prospectus”) which forms part of our Registration Statement on Form S-1 (Registration Statement No. 333-288816). This Prospectus Supplement is being filed to update and supplement the information included or incorporated by reference in the Prospectus with the information contained in the attached Current Report on Form 8-K, filed with the Securities and Exchange Commission (the “Securities and Exchange Commission”) on October 30, 2025 (the “Form 8-K”). Accordingly, we have attached the Form 8-K to this Prospectus Supplement.
This Prospectus Supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This Prospectus Supplement should be read in conjunction with the Prospectus, and if there is any inconsistency between the information in the Prospectus and this Prospectus Supplement, you should rely on this Prospectus Supplement.
Our common stock and public warrants are listed on Nasdaq Capital Market (“Nasdaq”) under the symbols “CERO” and “CEROW,” respectively. On October 29, 2025, the last quoted sale price of our common stock as reported on Nasdaq was $1.79 per share and the last quoted sale price of our public warrants as reported on Nasdaq was $0.0127 per warrant.
We are an “emerging growth company” under applicable federal securities laws and will be subject to reduced public company reporting requirements.
Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in “Risk Factors” beginning on page 8 of the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or determined if the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this Prospectus Supplement is October 30, 2025.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or Section 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2025
CERO THERAPEUTICS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | 001-40877 | 87-1088814 | ||
| (State or other jurisdiction of incorporation or organization) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
| 201 Haskins Way, Suite 230, South San Francisco, CA |
94080 | |
| (Address of principal executive offices) | (Zip Code) |
(650) 407-2376
Registrant’s telephone number, including area code
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common stock, par value $0.0001 per share | CERO | NASDAQ Capital Market | ||
| Warrants, each whole warrant exercisable for one two-thousandths of a share of common stock | CEROW | NASDAQ Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
As previously disclosed, on August 28, 2025, CERo Therapeutics Holdings, Inc., a Delaware corporation (the “Company”), received a letter from the staff at the Nasdaq Listing Qualifications department notifying the Company that such staff had determined that the Company does not comply with the minimum stockholders’ equity requirement of $2,500,000 (the “Stockholders’ Equity Requirement”) for continued listing on the Nasdaq Capital Market (“Nasdaq”) set forth in Nasdaq Rule 5550(b).
As also previously disclosed, on September 3, 2025, the Company requested a hearing to appeal such determination before a panel (the “Hearings Panel”). On October 29, 2025, the Company received the determination of the Hearings Panel to deny the Company’s request for the continued listing of its common stock. As a result, the common stock will be suspended from trading on Nasdaq at open of trading on October 31, 2025.
The Company has submitted a request for review of the Hearings Panel’s decision by the Nasdaq Listing and Hearing Review Council (the “Council”). The Company has also commenced the process of seeking to trade its shares of common stock on the OTC Markets. However, the Company can provide no assurance that the review by the Council will result in the continued listing of its shares of common stock or that the shares of common stock will be admitted for trading on the OTC Markets. The OTC Markets also are a less liquid market than Nasdaq, which may have a material adverse effect on the trading price and volume for the common stock. The Company is also considering listing alternatives, including applying to list its shares of common stock on another securities exchange.
The Company currently plans to continue its clinical trials, including the dosing of patients in such trials. As described previously by CERO, evidence gathered for CER-1236 in the first three AML cancer patients dosed at the initial low dose showed rapid cell expansion of CER-1236 in these patients, along with observation of no toxicity. Moreover the second patient, infused with three of the low doses in succession, continues on trial. The company believes these early stage observations support continued clinical development of CER-1236 at the planned higher dose, and is progressing on this plan. The Company is currently reviewing its cash resources and potential financing alternatives to fund its continued operations. The Company can provide no assurance that it will be able to obtain such financing on acceptable terms, or at all.
Item 8.01. Other Events.
On October 29, 2025, the Company issued a press release announcing the Hearings Panel’s determination. Such press release is filed as Exhibit 99.1 hereto and is hereby incorporated by reference herein.
Item 9.01 Exhibits.
(d) Exhibits.
| Exhibit Number |
Description | |
| 99.1 | Press Release dated October 29, 2025 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| CERO THERAPEUTICS HOLDINGS, INC. | ||
| By: | /s/ Chris Ehrlich | |
| Name: | Chris Ehrlich | |
| Title: | Chief Executive Officer | |
Dated: October 29, 2025
2
FAQ
What does CERO’s Prospectus Supplement cover?
What did Nasdaq decide about CERO’s listing (CERO)?
Will CERO continue trading elsewhere after Nasdaq suspension?
Did CERO appeal the Nasdaq decision?
What does CERO say about its clinical trials?
What are the recent market prices for CERO securities?
Is CERO seeking new financing?
